Dronabinol + palmidrol is under clinical development by Evero Health and currently in Phase II for Tourette Syndrome. According to GlobalData, Phase II drugs for Tourette Syndrome have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dronabinol + palmidrol’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dronabinol + palmidrol overview
Dronabinol in combination with palmidrol (THX-110) is under development for the treatment of Tourette syndrome (TS), obstructive sleep apnea (OSA), chronic low back pain, Alzheimer's disease and agitation. It is administered through the oral route as a buccal film. Dronabinol acts by targeting cannabinoid receptors CB1 and CB2. The drug candidate is developed based on (oral thin film) OTF technology and cannabinoid-centric platform.
Dronabinol in combination with palmidrol (THX-110) was under development for the treatment of obstructive sleep apnea (OSA), chronic low back pain in US.
For a complete picture of Dronabinol + palmidrol’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
